Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 22, Issue 8, Pages 1126-1138
Publisher
Elsevier BV
Online
2021-07-06
DOI
10.1016/s1470-2045(21)00332-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The importance of the RET gene in thyroid cancer and therapeutic implications
- (2021) Domenico Salvatore et al. Nature Reviews Endocrinology
- Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
- (2020) Jonathan K. Kish et al. ADVANCES IN THERAPY
- Current practice in patients with differentiated thyroid cancer
- (2020) Martin Schlumberger et al. Nature Reviews Endocrinology
- AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
- (2019) Francesca Collina et al. Cancers
- Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase 3 DECISION Trial
- (2019) Marcia S. Brose et al. CLINICAL CANCER RESEARCH
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
- (2019) Hye-Seon Oh et al. THYROID
- A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
- (2019) Nigel Fleeman et al. BMC CANCER
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differentiated Thyroid Cancer—Treatment: State of the Art
- (2017) Benedikt Schmidbauer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
- (2016) Sujata Narayanan et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- TheREToncogene in papillary thyroid carcinoma
- (2015) Jason D. Prescott et al. CANCER
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Molecular Targeted Therapies of Aggressive Thyroid Cancer
- (2015) Silvia Martina Ferrari et al. Frontiers in Endocrinology
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
- (2014) Maria E. Cabanillas et al. THYROID
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
- (2011) E. Avilla et al. CANCER RESEARCH
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search